Transit shipments of crude oil by pipelines through the territory of Ukraine to European countries in January-August 2018 decreased by 4.5%, or 409,500 tonnes, compared to the same period in 2017, to 8.692 million tonnes, PJSC Ukrtransnafta has said. The volume of oil pumping to the country’s oil refineries in January-August 2018 increased by 5.5%, 71,900 tonnes, 1.386 million tonnes, according to estimates of Interfax-Ukraine. Thus, the share of transit shipments in the total volume of oil transportation (10.077 million tonnes) in the eight months of 2018 was 86.2%, the share of pumping to the country’s oil refineries was 13.8%.
In August 2018, transit shipments of crude oil by pipelines through Ukraine decreased by 10.4% (125,000 tonnes) from August 2017, 1.08 million tonnes, pumping to the country’s refineries fell by 0.6% (1,100 tonnes), to 184,700 tonnes.
As reported, transit of oil through Ukraine to European countries in 2017 increased by 0.8% (by 114,900 tonnes) compared to the same period in 2016, to 13.937 million tonnes. The volume of oil transportation to the refineries of Ukraine in 2017 amounted to 2.097 million tonnes, which is 1.5-fold (690,600 tonnes) more than last year.
The growth of supplies inside the country is connected with the resumption of work of the Odesa-Kremenchuk section from March 10, 2017, which supplies Azeri Light oil to PJSC Ukrtatnafta. As reported, Ukrtransnafta, 100% managed by NJSC Naftogaz Ukrainy, is the operator of the country’s oil transportation system.
Ukrtransnafta’s trunk oil pipeline system, which includes pipes from 159 mm to 1,220 mm in diameters, stretches 4,767 kilometers and through 19 Ukrainian regions. It has annual capacity to accept 114 million tonnes for shipment and to supply 56.3 million tonnes to Europe.
Ukraine has exclusively developed medicines, which will be registered by regulatory agencies of Europe and the United States, Director General of YURiA-PHARM pharmaceutical company Dmytro Derkach.
Commenting on the study of the data about the market of drugs with insufficient evidence base initiated by Anti Corruption Action Centre (AntAC) with the support of the International Renaissance Foundation last week, he told Interfax-Ukraine that “according to the logic of the authors of this study, only drugs originating from the countries with regulatory authorities FDA (the United States) or EMA (the European Union) have the “proven effectiveness,” that is, Ukraine has no right to own inventions and developments.”
“The authors reject the idea that Ukraine has its own scientific and industrial potential, which is also capable of giving the world original and effective medicines or methods of treatment, and with the assistance of the state, capable of registering its products with the FDA and EMA regulatory authorities. It takes time and resources. Ukraine chose the path of European integration only a few years ago,” he said.
Derkach said that YURiA-PHARM is currently “on the way to register their products in the FDA and EMA.” Reosorbilact preparation is the process of registration, which is mentioned in the research materials as a drug that is among the top ten in terms of pharmacy sales, but at the same time, according to the authors of the study, not having clinically proven effectiveness.
According to Derkach, Reosorbilact is the development of domestic scientists of the Lviv Research Institute of Blood Pathology and Transfusion Medicine of the National Academy of Medical Sciences of Ukraine. As an original drug, it was registered early 2000s, having passed all the phases of clinical trials in accordance with the current legislation and legal acts of Ukraine. It has become the basis of numerous scientific research and defending candidate and doctoral dissertations during the past years. Currently, it is registered in Uzbekistan, Tajikistan, Azerbaijan, Kazakhstan, Moldova and Kyrgyzstan, in most countries of the former CIS.
According to Derkach, “in fact, the authors of this study question the professional competence of the domestic scientific medical and pharmaceutical community.”
YURiA-PHARM Corporation is a manufacturer of infusion solutions, medicines and medical products. It is among top ten leaders in pharmacy sales.
YURiA-PHARM is a member of the Association Manufacturers of Medications of Ukraine (AMMU).
Ukraine ranks fifth in the world in terms of honey production and is the leader in its production in Europe, Ukrainian Deputy Prime Minister for European and Euro-Atlantic Integration Ivanna Klympush-Tsintsadze’s office has said.
“Our country produces more than 100,000 tonnes per year, that is 6% of the world’s honey [output]. Today there are about 400,000 beekeepers with 4 million beehives in Ukraine,” it said on Facebook.
The office notes that the main producers of honey are eight regions: Vinnytsia, Donetsk, Dnipropetrovsk, Zaporizhia, Zhytomyr, Mykolaiv, Poltava, and Kirovohrad, which account for 70% of Ukrainian honey supplied to 35 countries.
“Most of the produce is exported by Ukraine to the United States, Germany, Poland, and France. In 2017, over 50,000 tonnes of honey was delivered to the EU countries alone (this includes over 5,000 tonnes within a duty-free quota),” the report said.
Public joint-stock company Farmak, the pharmaceutical company of Ukraine of the top three largest companies in the country, is mulling the possibility of acquiring a pharmaceutical company in Europe, acting CEO Volodymyr Kostiuk has said. “Now we are looking for a company which could be bought,” he told reporters.
Kostiuk said that this is the acquisition of an industrial company or a company with a product portfolio in Europe.
“Poland was the first step. Now we are looking at Hungary and Croatia. There is a concrete targeted profile. We are trying to meet it and select companies-candidates,” he said.
Kostiuk said that Farmak does not set the terms for acquiring the company and behaves thoughtfully regarding the cost of the asset.
“We are not in a hurry. We want to find the company that meets our plans as fully as possible,” he said.
In turn, Farmak Technical Director Andriy Hoi did not rule out that production of cancer treating medicines will be organized at the facilities of Farmak.
“These are very expensive medicines. They have a high production cost. These are highly active medications. Having several cancer treating medicines in our portfolio, including from post-Soviet solutions, we are working with leading Western companies regarding the localization of production of these medicines. We are thinking on starting a separate production line in the medium term outlook and a separate line of highly active medications,” he said.